Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Chris W. who wrote (2020)	3/11/1999 9:54:00 AM
From: Steve Harmon	Read Replies (1) \| Respond to of 2742

Maybe we should hire the monkey from PRCT?

To: Chris W. who wrote (2020)	3/17/1999 11:22:00 AM
From: Walter Morton	Read Replies (1) \| Respond to of 2742

The main cytokines which participate in the etiopathogenesis of aneurysms of the abdominal aorta (AAA) are: tumour necrotizing factor (TNF), interleukins 1b, 2, 6 and 8 (IL 1b, 2, 6, 8), platelet growth factor (PDGF) and endothelin 1, 2 (ET 1, 2). The objective of the presented work was to assess whether plasma levels of these cytokines can be used as endogenous markers of the size and symptomatology of AAA and also to what extent they correlated with hypertension which is a serious risk factor of AAA. During the three-year period (1995-1997) 86 patients with AAA were examined. The control group (n = 30) was formed by patients admitted for planned cholecystectomy. Plasma levels of all investigated cytokines with the exception of IL 8 in AAA differed markedly from the levels in the control group (p < 0.05-p < 0.0001). Changes in levels of IL8 and ET 1, 2 were significant in relation to the size of AAA (p < 0.05 and p < 0.01 resp.). The IL8 levels together with TNF in hypertonic patients correlated with the size of the AAA (p < 0.05 and p < 0.01 resp.), in normotonic subjects with the levels of IL 1b and IL2 (p < 0.05). The TNF levels were significant in symptomatic AAA (p < 0.05). The rising or declining levels of some plasma cytokines can serve as plasma markers of the growth and symptomatology of AAA.

To: Chris W. who wrote (2020)	4/24/1999 2:46:00 PM
From: Steve Harmon	Respond to of 2742

Have you ever heard of a Bankruptcy Chapter 11 CRAMDOWN?

To: Chris W. who wrote (2020)	9/29/1999 12:45:00 AM
From: Walter Morton	Respond to of 2742

The 10-K seems to imply that CIST is focused on R&D, cost reduction, and finding partners. R&D seems to have produced a relatively new product called ICE (that had been in development for years). PAI-2 is in Phase II clinical trials Using outside sources for R&D seems to be speeding up the process. Moving to a smaller building should reduced expenses greatly. CIST currently pays $126,000 per year just for rent. Subleasing will help also. Selling the equipment will generate cash. Perhaps they will sell it to RDS since RDS has a licence to manufacture and sell ICE products to the research market. The sale of the equipment could decrease future depreciation expense. If RSD takes our the manufacturing responsibility for ICE more employees could be eliminated (I mean free to find employment elsewhere.) Reducing the number of employees will reduce salary expense but will probably result in severance pay. As far as partners go, I suggest that CIST let some companies infringe upon the patent then sue them and settle out of court. Don't stop them from marketing the products just demand cash, licensing fee payments, and research collaborations. I'm just joking.